March 27, 2020

Bioness Inc.
Sageev George
Senior Regulatory Affairs Specialist
25103 Rye Canyon Loop
Valencia, California 91355

Re: K200482
Trade/Device Name: StimRouter Neuromodulation System
Regulation Number: 21 CFR 882.5870
Regulation Name: Implanted Peripheral Nerve Stimulator For Pain Relief
Regulatory Class: Class II
Product Code: GZF
Dated: February 25, 2020
Received: February 27, 2020

Dear Sageev George:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-
combination-products); good manufacturing practice requirements as set forth in the quality systems (QS)
regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for
combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-
542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part
803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-
mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including
information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See
the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE
by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Pamela D. Scott -S

Pamela Scott
Assistant Director
DHT5B: Division of Neuromodulation
and Physical Medicine Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
Indications for Use

The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.

Type of Use (Select one or both, as applicable)

☑ Prescription Use (Part 21 CFR 801 Subpart D)   ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff

PRASTaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3. 510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of 21 CFR §807.92:

I. Submitter Information

Company: Bioness Inc.
25103 Rye Canyon Loop
Valencia, CA 91355 USA
Phone Number: (661) 902-5324
Fax: (661) 362-4851
Email: mercedes.bayani@bioness.com

Contact: Sageev George
Regulatory Affairs Manager, Implantables
Phone Number: (661) 902-5336
Fax Number: (661) 362-4851
Email: sageev.george@bioness.com

Mercedes Bayani
Global Vice-President, Clinical & Regulatory Affairs
Phone Number: (661) 902-5324
Fax Number: (661) 362-4851
Email: mercedes.bayani@bioness.com

Date Prepared: February 25, 2020

II. Name of Device

Device Trade Name: StimRouter Neuromodulation System
Classification Name: Implantable peripheral nerve stimulator for pain relief
Common Name: Implantable Neurostimulator
Product Code: GZF
Regulation Number: 21 CFR §882.5870
Device Class: Class II
Panel Identification: Neurology

III. Predicate Device

Predicate Manufacturer: Bioness Inc.
Predicate Trade Name: StimRouter Neuromodulation System
Predicate 510(k): K190047
IV. Device Description

The StimRouter Neuromodulation System consists of two main parts – the implantable lead, and the external (to the body) accessories. Accessories for the StimRouter include a clinician programmer with software (CPS), a patient programmer, disposable hydrogel electrode patch, external pulse transmitter (EPT), and an EPT stimulation tester (EPTT). The StimRouter Neuromodulation System is provided with three labeling documents: the Clinician’s Guide, the Procedure Manual and the User’s Guide. Only the Procedure Manual has been modified to include an alternative implantation procedure for situations in which an open implantation of the implantable StimRouter Lead is indicated.

The Bioness StimRouter Neuromodulation System is intended to provide electrical stimulation via an implanted lead to a target peripheral nerve, for aid in the management of severe, intractable, chronic pain of peripheral nerve origin in adults, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.

The complete StimRouter System consists of three kits: A Lead and Lead Introducer Kit, a Clinician Kit and User Kit. The Lead Kit contains the StimRouter implantable multi-electrode lead with integrated receiver, used for peripheral nerve stimulation. The Lead receives an electrical signal transmitted transcutaneously by the EPT which is mounted on an electrode patch on the skin and delivers that electrical signal down the lead’s length to a target peripheral nerve. The Lead is supplied in Lead Loader that is used during intraoperative testing of the lead and to verify proper placement during implantation.

The Lead and Lead Introducer Kit consists of two stimulation probes, two stimulation cables, and introducer set, a lead adapter, a Tunneling Needle and a Tunneling Needle Stylet. The included tools and components allow for insertion of the StimRouter Lead and confirmation of optimal location of the stimulation electrode contacts of the StimRouter Lead.

The Clinician Kit is used for the programming of the StimRouter patient programmer and the EPT. The components of the Clinician Kit are a tablet PC with programming software and the accessories for connecting to the Patient Programmer and the EPT.

The User Kit contains the patient-use components of the StimRouter System. The components are the Patient Programmer and the EPT. After the EPT is programmed, the StimRouter electrode interfaces with the EPT and function to delivery stimulation to the implanted lead receiver.

V. Indications for Use
The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
VI. Comparison of Technological Characteristics

The subject device is a modified version of the StimRouter Neuromodulation System previously cleared in K190047. A comparison of the technological characteristics of the two is presented below. As noted in the Predicate Device Comparison Matrix below, other than the update of the Procedure Manual to include an alternative implantation procedure for situations in which an open implantation of the implantable StimRouter Lead is indicated, there are no other modifications with respect to the K190047 predicate all other technological characteristics are equivalent.

<table>
<thead>
<tr>
<th>Predicate Device Comparison</th>
<th>Subject Device (Modified StimRouter)</th>
<th>Predicate (StimRouter cleared in K190047)</th>
<th>Equivalency Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Bioness Inc.</td>
<td>Bioness Inc.</td>
<td>Same</td>
</tr>
<tr>
<td>510(k) number</td>
<td>To be Determined</td>
<td>K190047</td>
<td>-</td>
</tr>
<tr>
<td>Intended use</td>
<td>The StimRouter Neuromodulation System™ is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.</td>
<td>The StimRouter Neuromodulation System™ is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.</td>
<td>Same</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Implantable Lead and Lead Introducer Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packaging</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>StimRouter Lead</th>
</tr>
</thead>
<tbody>
<tr>
<td>StimRouter Lead</td>
</tr>
<tr>
<td>StimRouter Lead Receiver End</td>
</tr>
<tr>
<td>StimRouter Lead Stimulating End</td>
</tr>
<tr>
<td>Introduction method</td>
</tr>
<tr>
<td>Tunneled Needle and Tunneled Needle Stylet</td>
</tr>
<tr>
<td>Subject Device (Modified StimRouter)</td>
</tr>
<tr>
<td>-------------------------------------</td>
</tr>
<tr>
<td>StimRouter Loader</td>
</tr>
<tr>
<td>Stimulation Probe</td>
</tr>
<tr>
<td>Stimulation Cable</td>
</tr>
<tr>
<td>Introducer Set</td>
</tr>
<tr>
<td>Lead Adaptor</td>
</tr>
<tr>
<td>Gel Electrodes</td>
</tr>
</tbody>
</table>

**Clinician Kit**

**Clinician’s Programmer**

<table>
<thead>
<tr>
<th>Hardware</th>
<th>No changes</th>
<th>Vanquisher IP67 8-inch tablet running Window 10 Home</th>
<th>Same</th>
</tr>
</thead>
<tbody>
<tr>
<td>Software</td>
<td>No changes</td>
<td>Clinician Programmer Software used for storing patient info, session data, logs, patient stimulation profile, and programming, testing and saving of stimulation programs on tablet, and downloading of programs to Patient Programmer and EPT</td>
<td>Same</td>
</tr>
</tbody>
</table>

Stimulation Frequencies available for Patient Programmer and EPT stimulation programs: 1, 2, 5, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200 Hz
<table>
<thead>
<tr>
<th>Test</th>
<th>Subject Device (Modified StimRouter)</th>
<th>Predicate (StimRouter cleared in K190047)</th>
<th>Equivalency Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tester</td>
<td>No changes</td>
<td>Used to confirm EPT is delivering stimulation by providing audio feedback when stimulation is applied</td>
<td>Same</td>
</tr>
</tbody>
</table>

| User Kit |
|---------------------|--------------------------|---------------------------------|----------------------------|
| **External Pulse Transmitter (EPT)** |  |  |  |
| External Pulse Transmitter Description | No change | Generates stimulation signals, transmitting them transcutaneously through StimRouter Electrode to StimRouter Lead. Responds to wireless commands from Patient Programmer. Snaps onto StimRouter Electrode, Rechargeable lithium battery | Same |
| EPT Stimulation | No Change | EPT Max output: 30mA, Amplitude at Lead: 0-5mA (20% max pick-up ratio) Stimiation Signal: Monopolar, Biphasic, Charge Balanced, RF-based, Pulse Freq: 1-200 Hz, Max Compliance Voltage: 100V, Pulse Width: 70-500 µsec, Charge per phase limit:15 µC Ramp Up/Down feature | Same |
| EPT Stimulation Frequencies | No change | 1, 2, 5, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200 Hz | Same |

| **Patient Programmer** |  |  |  |
| Patient Programmer Description | No change | Communicates wirelessly (RF) with EPT to do the following: start/stop stimulation, adjust stimulation intensity, selection of one of 8 possible stimulation programs | Same |
| Patient Programmer Stimulation Frequencies | No change | 1, 2, 5, 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200 Hz | Same |
StimRouter Electrodes
No change
Reusable electrodes with gel pad that adhere to skin and transmit EPT stimulation signal to StimRouter Lead. Includes 2 snaps for EPT attachment
Same

Labeling: Update to Procedure Manual (MODIFIED FROM PREDICATE)

Addition of New Section Detailing Alternative Implantation Procedure for StimRouter Lead

Summary: The new section provides details on the implantation of the StimRouter Lead when open implantation of the Lead is indicated and treating physician believes that the StimRouter System would be useful in treating the pain associated with target nerve.

Implantation of Lead Procedure
The updated Procedure Manual still includes the minimally invasive procedure for Lead implantation but includes an alternate implant procedure for situations where open implantation of the Lead is indicated, for example when the area around the target nerve has been exposed (e.g., nerve decompression procedures). The new procedure details how the Lead can be placed and fixated next to target nerve and how the Tunneling Needle and Stylet can be used to place receiver end of Lead.

The Procedure Manual details a minimally invasive procedure for implanting the StimRouter Lead using a single stab incision, Stimulator Probe for target point identification, insertion of the Lead stimulating end using Introducer Set, and insertion of Lead receiver end using Tunneling Needle and Stylet.

Similar: The new procedure is being provided for situations in which the surgical field has been previously opened and does not introduce additional risks to the patient. Also, the new method of placing the Lead allows for similarly effective stimulation of target nerve and receipt of stimulation from EPT.

Design Control Activities
Bioness Inc. established, and continues to document and maintain, a system for identifying and addressing hazards associated with the design, manufacture and use of a medical device throughout its lifecycle. This system includes procedures for estimating, evaluating, controlling, and/or reducing risk such that the medical benefit outweighs the residual risk associated with the use of the devices that are marketed by Bioness Inc. These procedures address the risk management requirements of ISO 13485, ISO 14971:2012, the Medical Device Directive (MDD) and the Quality System Regulation (QSR).

This system was used to assess the impact of the modifications of the original StimRouter Neuromodulation System and to determine what verification and validation activities may be
Verification activities are not required, as there is no change to the design of the StimRouter.

Validation activities are not required – lead placement using this alternate approach is visible to the implanting physician due to the open nature of the procedure. The novel component involved during StimRouter lead implantation using this alternate technique is the process of using sutures and/or surgical glue to anchor the lead and prevent migration. These are commonly used surgical procedures employed by trained physicians and are not unique to the StimRouter implantation. As such, these process steps do not require usability testing.

The potential hazardous situation resulting from the alternate surgical approach has been identified as “Undesired motor neuron stimulation, due to poor placement of the lead during implant or migration after implant”. The specific harm associated with this failure mode has the same end effect (severity) as overstimulation of contraindicated nerves – a failure mode which is currently listed within the risk documentation (HA-00011) and the current state of the art information. As such, the Risk vs. Benefits assessment remains unchanged, where the benefits accrued from the use of the device outweigh any identified residual risk.

VII. Conclusions
Based on the system maintained by Bioness Inc. for identifying and addressing hazards associated with the design, manufacture and use of a medical device throughout its lifecycle, Bioness Inc. concludes that the Risks vs. Benefits assessment remains unchanged, where the benefits accrued from the use of the device outweigh any identified residual risk. Therefore, the subject device StimRouter Neuromodulation System, which has modifications as compared to the predicate StimRouter Neuromodulation System (cleared in K190047), is substantially equivalent to the predicate device in terms of safety and effectiveness for its indication of pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The subject device continues to not be intended to treat pain in the craniofacial region.